BlueCross BlueShield of Tennessee Medical Policy Manual

Intraocular Radiation Therapy for Age-Related Macular Degeneration

DESCRIPTION

Age-related macular degeneration (AMD) is characterized in its earliest stages by minimal visual impairment and the presence of large drusen and other pigmentary abnormalities on ophthalmoscopic examination. Two distinctively different forms of degeneration may be observed. The first, called the atrophic, areolar or dry form, evolves slowly. Atrophic AMD is the most common form of degeneration and may be a precursor of the more visually impairing exudative neovascular form, also referred to as disciform or wet AMD. The wet form is distinguished from the atrophic form by the development of choroidal neovascularization (CNV) and serous or hemorrhagic detachment of the retinal pigment epithelium. The risk of developing severe irreversible loss of vision is greatly increased by the presence of CNV.

Radiation therapy (e.g., NeoVista Epi-Rad90™ Ophthalmic System) is being studied as a way to treat CNV by focal delivery of radiation to a subfoveal choroidal neovascular lesion. Using a standard vitrectomy procedure, the cannula tip of a handheld (pipette-like) surgical device is inserted into the vitreous cavity and positioned under visual guidance over the target lesion. The radiation source (strontium-90) is advanced down the cannula until it reaches the tip, which is then held in place over the lesion for a “prescribed” time to deliver focused radiation. The system is designed to deliver a one-time peak dose of beta particle energy (24 Gy) for a target area 3 mm in depth and up to 5.4 mm in diameter. This is believed to be below the dose that is toxic to the retina and optic nerve, and radiation exposure outside of the target area is expected to be minimal.

Intraocular proton beam radiation therapy is being studied in clinical trials for the potential use in the management of choroidal neovascularization. Proton beam radiation is a type of linear line radiation therapy. The greatest amount of energy is expected to be released at the targeted site and should therefore cause less collateral damage to surrounding tissues and structures.

POLICY

IMPORTANT REMINDERS

ADDITIONAL INFORMATION

The U.S. Food and Drug Administration (FDA), under the provisions of an Investigational Device Exemption (IDE), granted the NeoVista Epi-Rad90 System™ investigational device to be used in order to collect safety and effectiveness data required to support a premarket approval application or a 510(k) submission to the FDA.

Well-designed studies with long-term follow-up published in peer-reviewed journals regarding the use of intraocular placement of a radiation source (e.g., NeoVista Epi-Rad90 System™) for the treatment of choroidal neovascularization are not available. It is not known if this technology improves net health outcomes.

There is a lack of published evidence of well-designed studies in peer review journals and randomized, controlled trials with long-term follow-up addressing the potential use of the proton beam therapy for the treatment of choroidal neovascularization.

SOURCES 

American Academy of Ophthalmology Retina/Vitreous Panel. (2015). Preferred Practice Pattern® Guidelines. Age-related macular degeneration. Retrieved February 15, 2017 from www.aao.org/ppp.

Avila, M. P., Farah, M. E., Santos, A., Carla, L., Fuji, G., Rossi, J., et al. (2012). Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina, 32 (1), 10-18. (Level 2 evidence - Independent study)

BlueCross BlueShield Association. Medical Policy Reference Manual. (3:2017). Intraocular radiation therapy for age-related macular degeneration (9.03.20). Retrieved March 5, 2018 from BlueWeb. (18 articles and/or guidelines)

Cantley, J., Hanlon, J., Chell, E., Lee, C., Smith, W., & Bolch, W. (2013). Influence of eye size and beam entry angle on dose to non-targeted tissues of the eye during stereotactic x-ray radiosurgery of AMD. Physical Medical Biology, 58 (19), 6887-6896. (Level 5 evidence - Industry supported)

Chalam, K. V., Balaiya, S., Malyappa, R. S., Hsi, W., Brar, V. S., & Murthy, R. K. (2011). Evaluation of choroidal endothelial cell proliferation after exposure to varying doses of proton beam radiation. Retina, 31 (1), 169-176. (Level 5 evidence)

Dugel, P. U., Petrarca, R., Bennett, M., Barak, A., Weinberger, D., Nau, J., et al. (2012). Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: Twelve-month safety and efficacy results. Ophthalmology, 119 (7), 1425-1431. (Level 2 evidence - Industry sponsored)

National Institute for Health and Clinical Excellence (NICE). (2011, December). Epiretinal brachytherapy for wet age-related macular degeneration. Retrieved March 19, 2013 from http://www.nice.org.uk/nice. 

National Institute for Health and Clinical Excellence (NICE). (2018, January). Age-related macular degeneration. Retrieved March 5, 2018 from http://www.nice.org.uk/nice.

Petrarca, R., & Jackson, T. (2011). Radiation therapy for neovascular age-related macular degeneration. Clinical Ophthalmology, 2011 (5), 57-63. (Level 5 evidence - Industry supported)

Petrarca, R., Dugel, P., Bennett, M., Barak, A., Weinberger, D., Nau, J., et al. (2014). Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina, 34 (5), 874-879. Abstract retrieved February 15, 2017 from PubMed database.

Slopsema, R., Mamalui, M., Zhao, T., Yeung, D., Malyappa, R., & Li, Z. (2014). Dosimetric properties of a proton beamline dedicated to the treatment of ocular disease. Medical Physics, 41 (1), 011707. Abstract retrieved February 15, 2017 from PubMed database.

ORIGINAL EFFECTIVE DATE:  7/10/2010

MOST RECENT REVIEW DATE:  4/12/2018

ID_BA

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.